Header Logo

Connection

Joan Merrill to Prednisone

This is a "connection" page, showing publications Joan Merrill has written about Prednisone.
Connection Strength

0.348
  1. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018 06; 77(6):883-889.
    View in: PubMed
    Score: 0.152
  2. How should lupus flares be measured? Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index. Rheumatology (Oxford). 2014 Dec; 53(12):2175-81.
    View in: PubMed
    Score: 0.116
  3. Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. Lupus. 2021 Jul; 30(8):1254-1263.
    View in: PubMed
    Score: 0.047
  4. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus. 2007; 16(6):401-9.
    View in: PubMed
    Score: 0.017
  5. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005 Nov 24; 353(21):2219-28.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.